Spyre Therapeutics, Inc. - 10-Q Filing

Spyre Therapeutics reports Q3 2026 financial results including updates on preferred stock and subsequent equity offerings.

SEC EDGAR ·

Tickers: $SYRE

Read the full article at SEC EDGAR

More Regulatory news